8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 20, 2014

SAVIENT PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-15313	13-3033811
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

400 Crossing Boulevard Bridgewater, NJ	08807
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (732) 418-9300

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

As previously announced, on October 14, 2013, Savient Pharmaceuticals, Inc. (the “Company”) and its subsidiary, Savient Pharma Holdings, Inc. (collectively, the “Debtors”), filed voluntary petitions (the “Chapter 11 Cases”) for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).

On February 20, 2014, the Debtors filed their monthly operating report for the period of January 1, 2014 through January 31, 2014 (the “Monthly Operating Report”) with the Bankruptcy Court. The Monthly Operating Report is attached hereto as Exhibit 99.1.

Cautionary Statement Regarding the Monthly Operating Report

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Report, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The Monthly Operating Report is limited in scope and has been prepared solely for the purpose of complying with requirements of the Bankruptcy Court. The Monthly Operating Report was not reviewed by independent accountants, is in a format prescribed by applicable bankruptcy laws, and is subject to future adjustment. The financial statements in the Monthly Operating Report are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Report also contains information for periods which are shorter or otherwise different from the historical periods required in the Company’s reports pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such information might not be indicative of the Company’s financial condition or operating results for a period that would be reflected in the Company’s financial statements or in its reports pursuant to the Exchange Act. Information set forth in the Monthly Operating Report should not be viewed as indicative of future results.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and Exhibit 99.1 hereto (collectively, this “Current Report”) may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations, estimates, forecasts, and projections as well as the current beliefs and assumptions of the Company’s management. Forward-looking statements may be identified by words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “may,” “predict,” “will,” “would,” “could,” “should,” “target” and similar expressions. All statements contained in this Current Report that are not statements of historical fact and other estimates, projections, future trends and the outcome of events that have not yet occurred referenced in this Current Report should be considered forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties, including, among others, the potential adverse impact of the Chapter 11 Cases on the Company’s liquidity, changes in the Company’s ability to meet financial obligations during the Chapter 11 process or to maintain contracts that are critical to the Company’s wind-down of its affairs, the outcome or timing of the Chapter 11 process, the effect of the Chapter 11 Cases or the sale of substantially all of the Company’s assets to Crealta Pharmaceuticals LLC (the “Sale Transaction”) on the Company’s relationships with third parties, regulatory authorities, employees and consultants in connection with the Company’s wind-down of its affairs, proceedings that may be brought by third parties in connection with the Chapter 11 process, the ability of the Company to fund the wind-down of its affairs and the timing or amount of any distributions to the Company’s stakeholders. For a discussion of some of the additional risks and important factors that the Company believes could cause actual results or events to differ from the forward-looking statements that it makes, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events to differ from those contained in any forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking statements contained in this Current Report. Any forward-looking statements speak only as of the date of this Current Report. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Limitation on Incorporation by Reference

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of

1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

Additional Information regarding the Chapter 11 Cases

Additional information regarding the Chapter 11 Cases is available at www.gcginc.com/cases/svnt. This link is provided for convenience only. Such information shall not be deemed to be incorporated by reference herein. As a result of the consummation of the Sale Transaction, investors should no longer refer to the Company’s former company website for information.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

99.1 Monthly Operating Report for the Period of January 1, 2014 through January 31, 2014, dated February 20, 2014.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SAVIENT PHARMACEUTICALS, INC.
Date: February 21, 2014	By:	/s/ Mathew C. Bazley
		Name:	Mathew C. Bazley
		Title:	Chief Liquidation Officer, President and Secretary

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Monthly Operating Report for the Period of January 1, 2014 through January 31, 2014, dated February 20, 2014.

EX-99.1

Exhibit 99.1

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

-  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -	x
	:
In re:	:	Chapter 11
	:
SAVIENT PHARMACEUTICALS, INC.,	:	Case No. 13-12680 (MFW)
et al.,	:
	:	Jointly Administered
Debtors.1	:
-  -  -  -  -  -  -  -  -  -  -  -   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -  -	: x

NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT

FOR THE PERIOD OF JANUARY 1, 2014 THROUGH JANUARY 31, 2014

PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the above-captioned cases

(collectively, the “Debtors”) filed today the Debtors’ Monthly Operating Report for the Period of January 1,

2014 through January 31, 2014, a copy of which is attached hereto as Exhibit A (the “Monthly Operating

Report”).

Dated:	Wilmington, Delaware
	February 20, 2014

COLE, SCHOTZ, MEISEL, FORMAN

  & LEONARD, P.A.

/s/ David R. Hurst                                

David R. Hurst (I.D. No. 3743)

J. Kate Stickles (I.D. No. 2917)

500 Delaware Avenue, Suite 1410

Wilmington, Delaware 19801

Telephone: (302) 652-3131

Facsimile: (302) 652-3117

Counsel for Debtors and  Debtors-in-Possession

¹  The Debtors and the last four digits of their respective taxpayer identification numbers are as follows: Savient Pharmaceuticals, Inc. (3811); and Savient Pharma Holdings, Inc. (0701). The address of the Debtors’ corporate headquarters is 400 Crossing Boulevard, 4^th Floor, Bridgewater, New Jersey 08807.

51790/0001-10332996v1

EXHIBIT A

Monthly Operating Report

51790/0001-10332996v1

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re: Savient Pharmaceuticals, Inc., et al	Case No.13-12680 (MFW)
	Reporting Period: January 1, 2014 - January 31, 2014

MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document   Attached	Explanation   Attached**	Affidavit/Supplemen   t Attached**
Schedule of Cash Receipts and Disbursements	MOR-1	Yes
Bank Reconciliation (or copies of debtor’s bank reconciliation	MOR-1a	Yes
Schedule of Professional Fees Paid	MOR-1b	Yes
Copies of bank statements		No	Yes
Cash disbursements journals		No	Yes
Statement of Operations	MOR-2	Yes
Balance Sheet	MOR-3	Yes
Status of Postpetition Taxes	MOR-4	Yes
Copies of IRS Form 6123 or payment receipt		No	Yes
Copies of tax returns filed during reporting period		No	Yes
Summary of Unpaid Postpetition Debts	MOR-4	Yes
Listing of aged accounts payable	MOR-4	Yes
Accounts Receivable Reconciliation and Aging	MOR-5	Yes
Debtor Questionnaire	MOR-5	Yes
** Explaination and Affidavit/Supplement are attached as a part of the Company’s General Notes

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents

are true and correct to the best of my knowledge and belief.

Signature of Debtor	Date
Signature of Joint Debtor	Date
/s/ Mathew C. Bazley	February 20, 2014
Signature of Authorized Individual*	Date
Mathew C. Bazley	Chief Liquidation Officer, President, and Secretary
Printed Name of Authorized Individual	Title of Authorized Individual

MOR_Cover MOR COVER (04/07)

In re: Savient Pharmaceuticals, Inc. et al.	Case Nos. 13-12680, 13-12681 (MFW)
	Reporting Period: 1/1/2014 - 1/31/2014

NOTES TO THE MONTHLY OPERATING REPORT

General Notes

Debtors. Debtor Savient Pharmaceuticals, Inc. is referred to herein as “Savient” or “SPI,” and Debtor Savient Pharma Holdings, Inc. is referred to herein as “SPHI.”

Debtor-in-Possession Financial Statements. The Debtors’ financial statements and supplemental information contained herein are unaudited, preliminary and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects.

Accounting Standards Codification, (“ASC”) 852-10, Reorganizations, which incorporated the guidance in American Institute of Certified Public Accountants Statement of Position 90-7, Financial Reporting by Entities in Reorganization under the Bankruptcy Code, (SOP 90-7), is applicable to companies in chapter 11 and generally does not change the manner in which financial statements are prepared. It does require, however, that the financial statements for periods subsequent to the filing of the chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of business.

The Debtors’ financial statements contained herein have been prepared in accordance with the guidance in ASC 852-10. The unaudited financial statements have been derived from the books and records of the Debtors. This information, however, has not been subject to procedures that would typically be applied to financial information presented in accordance with U.S GAAP, and upon the application of such procedures, the Debtors believe that the financial information could be subject to changes, and these changes could be material. The information furnished in this report includes primarily normal recurring adjustments, but does not include all of the adjustments that would be typically made in accordance with U.S. GAAP.

The results of operations contained herein are not necessarily indicative of results that are expected from any other period or for the full year and may not necessarily reflect the combined results of operations, financial position and cash flows of the Debtors in the future.

Intercompany Transactions. Receivables and payables between the Debtors and/or Non-Debtors have not been eliminated.

Liabilities Subject to Compromise. As a result of the chapter 11 filings, the payment of prepetition indebtedness is subject to compromise or other treatment under a plan of reorganization or liquidation.

The determination of how liabilities ultimately will be settled and treated cannot be made until the United States Bankruptcy Court for the District of Delaware approves a chapter 11 plan of reorganization or liquidation. Accordingly, the ultimate amount of such liabilities is not determinable at this time. Revenues, expenses, realized gains and losses and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the Debtors’ statements of operations.

51790/0001-10332990v1

The Debtors’ balance sheets, in addition, must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from postpetition liabilities. Liabilities that may be affected by a plan of reorganization or liquidation must be reported at the amounts expected to be allowed, even if they may be settled for lesser amounts. In addition, cash provided by reorganization items must be disclosed separately in the Debtors’ statements of cash flows. The amounts currently classified as liabilities subject to compromise are preliminary and may be subject to future adjustments depending on Court actions, further developments with respect to disputed claims, determinations of the secured status of certain claims, the values of any collateral securing such claims, rejection of executory contracts, continued reconciliation and other events.

While in bankruptcy, the Debtors expect their financial results to continue to be volatile as asset impairments, asset dispositions, contract terminations and rejections and claims assessments may significantly impact the Debtors’ financial statements. As a result, the Debtors’ historical financial performance is likely not indicative of its financial performance after the date of the chapter 11 filings.

Notes to MOR-1a

Copies of Bank Statements and Cash Disbursements Journals. The copies of the Debtors’ bank statements and cash disbursement journals are voluminous and not included herein, but will be provided upon request.

Notes to MOR-4

Copies of IRS Form 6123; Tax Returns. To be provided upon request.

Savient MOR-4. The postpetition accounts payable reported for Debtor Savient Pharmaceuticals, Inc. represent trade vendor invoices that have been entered into the Debtor’s accounts payable system and does not include accruals for invoices not yet received or approved.

2

51790/0001-10332990v1

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS

	BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED January 31, 2014																				CUMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH JANUARY 31, 2014
	PNC			AR Lockbox		Fidelity		Wells Fargo		Wells Fargo Utilities		PNC -LOC (secure LOC)		PNC - LOC (covers fees)		Petty Cash		TOTAL			TOTAL
CASH BEGINNING OF MONTH	$	10,388,517		$	-	$	-	$	6,209,254	$	14,228	$	1,304,340	$	150,222	$	1,000	$	18,067,561		$	12,255,382
RECEIPTS
TRANSFER FROM SUB (SPHI)		-			-		-		-		-						-		-			13,700,356
ACCOUNTS RECEIVABLE		730,186			1,438,474		-		-		-						-		2,168,660			7,200,942
TRANSFERS (FROM FIDELITY MM)		-			-		-		-		-						-		-			383,692
STATE MEDICAID REFUNDS		-			-		-		-		-						-		-			98,009
REFUNDS FROM VENDORS		7,812			-		-		-		-						-		7,812			84,006
ACTAVIS-SALES (oxandrolone royalty)		-			-		-		-		-						-		-			69,540
KINERET CO-PROMOTE REVENUE		-			-		-		-		-						-		-			61,859
TRANSFER FROM OPERATING ACCOUNT		-			-		-		-		-						-		-			14,228
COBRA PAYMENTS FROM EMPLOYEES		6,327			-		-		-		-						-		6,327			31,495
AMEX RECEIPTS FROM EMPLOYEES		7,250			-		-		-		-						-		7,250			8,208
RECEIPTS FROM EMPLOYEE ADVANCES		-			-		-		-		-						-		-			500
EQUIPMENT PURCHASES BY EMPLOYEES		-			-		-		-		-						-		-			400
DIVIDENDS ON MONEY MARKET ACCOUNT		-			-		-		-		-						-		-			123
INVESTMENT INCOME FROM CD PORFOLIO		-			-		-		-		-						-		-			576
Proceeds from Sales to Crealta		116,282,138			-		-		-		-						-		116,282,138			116,282,138
		-			-		-		-		-						-		-			-
TOTAL RECEIPTS	$	117,033,714		$	1,438,474	$	-	$	-	$	-	$	-	$	-	$	-	$	118,472,188		$	137,936,073
DISBURSEMENTS
PAYMENTS TO NOTE HOLDERS		116,103,950			435,000		-		-		-						-		116,538,950			124,538,950
NET PAYROLL		1,220,854			-		-		-		-						-		1,220,854			3,646,919
PROFESSIONAL FEES		2,256,769			-		-		-		-						-		2,256,769			2,819,106
CONSULTANT FEES		9,296
VENDOR PAYMENTS		837,840			-		-		-		-						-		837,840			1,385,311
EMPLOYEE BENEFITS (401K & Health)		118,225			-		-		-		-						-		118,225			578,218
STATE AGENCIES AND TAX PAYMENTS		-			-		-		-		-						-		-			453,007
TRANSFERS TO OPERATING ACCOUNT		-			-		-		-		-						-		-			383,692
RENT		15,274			-		-		-		-						-		15,274			384,702
CONCUR (employee expenses)		46,713			-		-		-		-						-		46,713			270,885
PAYMENTS TO BOARD OF DIRECTORS		73,010			-		-		-		-						-		73,010			178,136
FUNDING FOR CO-PAY PROGRAM		-			-		-		-		-						-		-			36,872
AMERICAN EXPRESS (employee expenses)		2,838			-		-		-		-						-		2,838			28,753
AMERIFLEX (flex spending)		6,240			-		-		-		-						-		6,240			28,630
TRANSFER TO WELLS FARGO UTILITY ACCOUNT		-			-		-		-		-						-		-			14,228
EMPLOYEE EDUCATION REIMBURSEMENT		-			-		-		-		-						-		-			12,985
STORAGE AND WAREHOUSE (INVENTORY)		1,665			-		-		-		-						-		1,665			4,995
BANK FEES		11,732			-		-		-		-						-		11,732			14,222
SHIPPING AND DELIVERY		-			-		-		-		-						-		-			2,205
TOTAL DISBURSEMENTS	$	120,704,406		$	435,000	$	-	$	-	$	-	$	-	$	-	$	-	$	121,130,110		$	134,781,816
NET CASH FLOW	$	(3,670,692	)	$	1,003,474	$	-	$	-	$	-	$	-	$	-	$	-	$	(2,657,922	)	$	3,154,257
(RECEIPTS LESS DISBURSEMENTS)		-			-		-		-		-		-		-		-		-			-
CASH - END OF MONTH	$	6,717,825		$	1,003,474	$	-	$	6,209,254	$	14,228	$	1,304,340	$	150,222	$	1,000	$	15,409,639		$	15,409,639
*    COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE
DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL COLUMN)								FOR THE MONTH ENDED JANUARY 31, 2014		FOR THE MONTH ENDED December 31, 2013		FOR THE MONTH ENDED NOVEMBER 30, 2013		FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013							CUMMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH JANUARY 31, 2014
TOTAL DISBURSEMENTS								$	121,130,110	$	2,492,701	$	2,396,428	$	8,762,577						$	134,781,816
LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS											-		384,867		13,053							397,920
LESS: PAYMENT OF U.S. TRUSTEE FEES									13,325													13,325
PLUS: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e., from escrow accounts)									-		-		-		-							-
									-		-		-		-							-
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES								$	121,130,110	$	2,492,701	$	2,011,561	$	8,749,524						$	134,370,571

SAVIENT_MOR_1 FORM MOR-1 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SPHI (13-12681): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS

	BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED JANUARY 31, 2014		BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED DECEMBER 31, 2013		BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED NOVEMBER 30, 2013		BANK ACCOUNT ACTIVITY FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013
	PNC		PNC		PNC		PNC
CASH BEGINNING OF MONTH	$	3,241,587	$	3,241,584	$	3,241,584	$	16,941,887
RECEIPTS
DIVIDENDS ON MONEY MARKET ACCOUNT		-		3		-		73
		-		-		-		-
TOTAL RECEIPTS	$	-	$	3	$	-	$	73
DISBURSEMENTS
TRANSFERS TO SAVIENT OPERATING ACCOUNT		-		-		-		13,700,356
BANK FEES		-		-		-		20
SHIPPING AND DELIVERY		-		-		-		-
TOTAL DISBURSEMENTS	$	-	$	-	$	-	$	13,700,376
NET CASH FLOW	$	-	$	3	$	-	$	(13,700,303)
(RECEIPTS LESS DISBURSEMENTS)		-		-		-		-
CASH - END OF MONTH	$	3,241,587	$	3,241,587	$	3,241,584	$	3,241,584
*  COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE
DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL COLUMN)	CURRENT MONTH JANUARY 31, 2014		CURRENT MONTH DECEMBER 31, 2013		FOR THE MONTH ENDED NOVEMBER 30, 2013		FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013
TOTAL DISBURSEMENTS	$	-	$	-	$	-	$	13,700,376
LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS		-		-		-		-
LESS: TRANSFERS BETWEEN ACCOUNTS		-		-		-		13,700,356
		-		-		-		-
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES	$	-	$	-	$	-	$	20

SPHI_MOR_1 FORM MOR-1 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): BANK RECONCILIATIONS

																		PNC - Letter of Credit			PNC - Letter Of Credit
		PNC				PNC Lockbox			Fidelity			Wells Fargo			Wells Fargo Utilities			(secure LOC)			(covers fees)			Petty Cash
	#				#			#			#			#			#			#			#
BALANCE PER BOOKS		$	6,717,825			$	1,003,474		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	1,000
BANK BALANCE		$	6,766,660			$	1,003,474		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	-
(+) DEPOSITS IN TRANSIT (ATTACH LIST)			-				-			-			-			-			-			-			-
(-) OUTSTANDING CHECKS (ATTACH LIST)			(48,835	)			-			-			-			-			-			-			-
OTHER (ATTACH EXPLANATION)			-				-			-			-			-			-			-			-
ADJUSTED BANK BALANCE *		$	6,717,825			$	1,003,474		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	-
* Adjusted bank balance must equal
balance per books
DEPOSITS IN TRANSIT	Date		Amount		Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount
NONE
CHECKS OUTSTANDING	Ck. #		Amount		Ch. #		Amount	Ch. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount
Total Outstanding Checks		$	48,835

Savient MOR_1a FORM MOR-1a (04/07)

SPHI MOR_1a FORM MOR-1a (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SPHI (13-12681): BANK RECONCILIATIONS

	PNC
	#
BALANCE PER BOOKS		$	3,241,587
BANK BALANCE		$	3,241,587
(+) DEPOSITS IN TRANSIT (ATTACH LIST)			-
(-) OUTSTANDING CHECKS (ATTACH LIST)			-
OTHER (ATTACH EXPLANATION)			-
ADJUSTED BANK BALANCE *		$	3,241,587
* Adjusted bank balance must equal
balance per books
DEPOSITS IN TRANSIT	Date		Amount
NONE
CHECKS OUTSTANDING	Ck. #		Amount
NONE

MOR-1a (Addendum)

Savient (13-12680): Open Bank Accounts as of January 31, 2014

Account number	Bank	Type	Book Balance
xxxxxx9201	Wells Fargo	U.S. Treasury Money Market Fund	$	6,209,254
xxxxxx5904	Wells Fargo	Utilities (Bankruptcy account)	$	14,228
xxxxxx5687	PNC	Savient Inc Operating Account	$	6,717,825
xxxxxx1019	PNC	AR Lockbox	$	1,003,474
xxxxxx2019	PNC	Letter of Credit (Secure LOC)	$	1,304,340
xxxxxx2548	PNC	Letter of Credit (Covers fees)	$	150,222

MOR-1a (Addendum)

SPHI (13-12681): Open Bank Accounts as of January 31, 2014

Account number	Bank	Type	Book Balance
xxxxxx6418	PNC	SPHI Operating Account	$	3,241,587

In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: January 1, 2014 - January 31, 2014
	SAVIENT (13-12680): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

Payee

Amount

Check

Amount Paid

Cumulative-To-Date

Period Covered

Approved

Payor

Number

Date

Fees

Expenses

Fees

Expenses

Mary Bordeaux Consulting

10/15-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67595

11/21/2013

600

-

-

-

Mary Bordeaux Consulting

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67651

12/18/2013

1,000

-

-

-

Mary Bordeaux Consulting

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67724

1/9/2014

800

2,400

-

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

11/4/2013

63,400

6,600

-

-

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

11/5/2013

18,000

7,000

-

-

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

12/3/2013

80,000

-

-

-

The Garden City Group,

10/15-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/3/2014

288,234

57,006

449,634

70,606

Weiss, Rifkind,

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

11/19/2013

95,901

1,878

-

-

Weiss, Rifkind,

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/23/2013

189,132

5,669

Weiss, Rifkind,

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/27/2014

237,592

4,751

522,625

12,298

Maples and Calder

11/1-11/29/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

14,732

-

14,732

-

Shannon, Gracy and Ratlif

10/15-10/26/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

564

68

-

-

Shannon, Gracy and Ratlif

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67736

1/9/2014

1,595

141

2,159

209

The Pine Hill Group

10/15-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/13/2013

62,530

-

-

-

The Pine Hill Group

12/1-12/14/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

15,263

-

-

-

The Pine Hill Group

12/15/2013-1/17/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/9/2014

28,788

-

-

-

The Pine Hill Group

1/1-1/17/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/21/2014

4,625

-

-

-

The Pine Hill Group

1/20-1/24/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/30/2014

5,828

-

117,033

-

Cole, Schotz, Meisel, Forman & Leonard, P.A.

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/28/2014

284,120

2,514

284,120

2,514

Deloitte Tax LLP

10/14-11/25/2013

N/A

Savient Pharmaceuticals, Inc.

67710

1/9/2014

7,500

300

Deloitte Tax LLP

11/25-12/16/2013

N/A

Savient Pharmaceuticals, Inc.

67710

1/9/2014

18,670

747

26,170

1,047

Joele Frank Wilkinson Brimmer

10/11-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67719

1/9/2014

25,772

6,219

Joele Frank Wilkinson Brimmer

11/01-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67719

1/9/2014

5,101

385

Joele Frank Wilkinson Brimmer

12/01-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67756

1/17/2014

21,694

9,064

52,567

15,667

Kaufman Dolowich & Voluck, LLP

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67720

1/9/2014

2,075

Kaufman Dolowich & Voluck, LLP

11/01-11/22/2013

N/A

Savient Pharmaceuticals, Inc.

67720

1/9/2014

4,171

6,246

Lowenstein Sandler, LLP

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67723

1/9/2014

1,851

Lowenstein Sandler, LLP

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67723

1/9/2014

2,897

Lowenstein Sandler, LLP

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67783

1/31/2014

131

4,879

Skadden, Arps, Slate, Meagher & Flom LLP

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/28/2014

1,185,074

19,552

1,185,074

19,552

Sterne, Kessler, Goldstein, Fox

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67738

1/9/2014

1,958

1,958

Young Conaway Stargatt & Taylor, LLP

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/14/2014

27,001

616

27,001

616

SAVIENT MOR_1b FORM MOR-1b (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

                        SPHI (13-12681): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

		Amount		Check		Amount Paid		Year-To-Date
Payee	Period Covered	Approved	Payor	Number	Date	Fees	Expenses	Fees	Expenses
No professional fee payments were made by the Debtor during the Reporting Period 1/1/14 through 1/31/14

SPHI MOR_1b FORM MOR-1b (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): STATEMENT OF OPERATIONS

(Income Statement)

REVENUES	For The Month Ended January 31, 2014		Cumulative Filing to Date October 15, 2013 Through January 31, 2014
Gross Revenues	$	1,638,489	$	10,307,196
Less: Gross-to-Net Adjustments		261,707		3,430,184
Net Revenue	$	1,376,782	$	6,877,012
COST OF GOODS SOLD				-
Beginning Inventory	$	1,037,458	$	4,516,751
Add: Purchases		-		-
Add: Cost of Labor		-		-
Add: Other Costs (attach schedule)		-		-
Less: Ending Inventory	$	-	$	3,308,559
Change in Inventory		1,037,458		1,208,192
Reclass Sales to Gain/Loss		(1,012,971)
				-
Add: Royalties (MVP & DUKE)		-		451,915
Add: Royalties (Office of the Chief Scientist of Israel)		-		177,122
Add: Management fee allocation to COGS		-		93,375
Add: Stability testing		-		79,331
Add: Distribution fees		16,787		75,982
Cost of Goods Sold	$	41,274	$	1,072,946
Gross Profit	$	1,335,508	$	5,804,066
OPERATING EXPENSES				-
Research and Development Related Expenses:				-
Investigator grants	$	-	$	150,000
QC & Stability testing		-		60,360
CRO costs		-		111,312
Pharmacovigilance		-		54,744
Process development and Improvement		-		23,878
IP Related		1,479		12,836
Central labs		2,194		8,958
REMS Communication and assessment		-		7,590
Publications		1,969		6,891
Research		1,407		1,407
Total Research and Development Related Expenses	$	7,049	$	437,976
			$	-
Selling and Marketing Related Expenses:				-
Pricing and reimbursement	$	3,425	$	171,166
Exhibit booth		-		69,019
Speakers programs		-		52,882
Maketing and other promotional activity		16,016		61,261
Medical meetings and symposia		-		38,167
Medical education		7,485		26,193
Market research		-		5,585
Publications		-		78
Total Selling and Marketing Related Expenses	$	26,926	$	424,351
			$	-
General and Administrative Related Expenses:				-
Compensation and related benefits and taxes	$	925,663	$	3,820,261
Insurance (amortization of prepaid insurance)		225,020		810,143
Share-based compensation (SFAS 123-R expense)		87,000		653,522
Sales force commissions		-		351,582
Occupancy		119,181		425,083
Travel and entertainment		18,443		235,641
Accrued Board of Directors’ cash payments & meeting fees		13,000		173,054
Outside consulting services		21,481		137,126
Corporate communications and investor relations		33,055		118,554
Legal		412		76,975
Licenses and information		7,801		58,090
Communications (Utilities)		6,892		46,218
General office expenses and office supplies		34,390		53,848
Postage and Shipping		2,072		6,041
Total General and Administrative Related Expenses:	$	1,494,410	$	6,966,138
Total Operating Expenses Before Depreciation	$	1,528,385	$	7,828,465
Depreciation and amortization		33,323		110,582
Net Loss Before Other Income & Expenses	$	(226,200)	$	(2,134,981)
				-
OTHER INCOME AND (EXPENSES)				-
Dividend income	$	-	$	699
Interest Expense on capital leases		-		(2,488)
Bank charges		(11,812)		(14,302)
Net Profit (Loss) Before Reorganization Items	$	(238,012)	$	(2,151,072)
REORGANIZATION ITEMS				-
Proceed from Sale to Crealta	$	(116,282,138)	$	(116,282,138)
Distribution to Noteholders	$	116,538,950	$	124,538,950
Professional Fees		5,509,636		10,506,916
Cure Cost		(2,393,690)		(2,393,690)
Accrual Adjustments (Changes in estimates)		(901,303)
U. S. Trustee Quarterly Fees		13,325		13,325
Interest Earned on Accumulated Cash from Chapter 11 (see continua		-		-
Gain (Loss) from Sale of Equipment		(3,046,863)		(3,046,863)
Total Reorganization Expenses	$	(562,083)	$	12,435,197
Income Taxes				-
Net Profit (Loss)	$	324,071	$	(14,586,269)

*“Insider” is defined in 11 U.S.C. Section 101(31).

SAVIENT_MOR_2 FORM MOR-2 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January

SPHI (13-12681): STATEMENT OF OPERATIONS

(Income Statement)

REVENUES	For The Month Ended January 31, 2014		Cumulative Filing to Date October 15, 2013 Through January 31, 2014
NOT APPLICABLE	$	-	$	-
			$	-
COST OF GOODS SOLD				-
NOT APPLICABLE	$	-	$	-
			$	-
OPERATING EXPENSES (NONE NOTED FOR THE CURRENT PERIOD)				-
			$	-
General and Administrative Related Expenses:				-
Compensation and related benefits and taxes	$	-	$	-
Share-based compensation		-		-
Accrued sales commissions (SFAS 123-R expense)		-		-
Insurance (Amortization of prepaid insurance)		-		-
Travel and entertainment		-		-
Occupancy		-		-
Outside consulting services		-		-
General office expenses and office supplies		-		-
Accrued Board of Directors’ cash payments		-		-
Communications (Utilities)		-		-
Legal expenses		-		-
Corporate communications and investor relations		-		-
Total General and Administrative Related Expenses:	$	-	$	-
Total Operating Expenses Before Depreciation	$	-	$	-
Depreciation and amortization		-		-
Net Loss Before Other Income & Expenses	$	-	$	-
				-
OTHER INCOME AND (EXPENSES)				-
Dividend income	$	-	$	76
Interest Expense on capital leases		-		-
Bank charges		-		(20	)
Net Profit (Loss) Before Reorganization Items	$	-	$	56
REORGANIZATION ITEMS				-
Impairment of intercompany note receivable from Parent (Savient)	$	-	$	13,700,356
		-		-
Total Reorganization Expenses	$	-	$	13,700,356
Income Taxes		-		-
Net Profit (Loss)	$	-	$	(13,700,300	)

*“Insider” is defined in 11 U.S.C. Section 101(31). -      

SPHI_MOR 2 FORM MOR-2 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): BALANCE SHEET

ASSETS	BOOK VALUE AT JANUARY 31, 2014			BOOK VALUE ON PETITION DATE
CURRENT ASSETS
Cash and cash equivalents
Petty cash	$	1,000		$	1,000
PNC Bank business operating account		6,717,825			4,207,573
PNC AR Lockbox		1,003,474
Wells Fargo utilities account		14,228			-
Fidelity U.S. Treasury money market account		-			383,689
Wells Fargo money market account		6,209,254			3,169,442
PNC Letter of Credit (Acct # 31900362019 - Secure the LOC)		1,304,340			1,304,340
PNC Letter of Credit (Acct #31800362548 - Covers LOC Fees)		150,222			150,222
Total cash and cash equivalents	$	15,400,343		$	9,216,266
Short-term investments
Wells Fargo CD Portfolio	$	-		$	3,039,116
Total short-term investments	$	-		$	3,039,116
					-
Accounts receivable (Net)	$	6,010,810		$	7,088,730
Inventories (Net)	$	-		$	1,208,192
Prepaid expenses and other current assets
Prepaid D&O insurance	$	2,275,700		$	2,603,465
Professional retainers		943,243			1,552,562
Other receivables non-trade		291,406			622,746
Prepaid-other		108,707			313,115
Prepaid-other insurance		119,511			221,089
Prepaid rent		9,667			65,698
Prepaid marketing costs (YNF- Co-pay program)		-			83,424
Prepaid product liability insurance		-			96,338
Advances to employees		600			600
Total prepaid expenses and other current assets	$	3,748,834		$	5,559,037
TOTAL CURRENT ASSETS	$	25,159,987		$	26,111,341
PROPERTY AND EQUIPMENT
Office equipment	$	656,229		$	656,229
Other furniture and fixtures		6,005			6,005
Leasehold Improvements		1,496,216			1,496,216
Capital lease assets		212,770			212,770
Less Accumulated Depreciation		(804,099	)		(684,933	)
TOTAL PROPERTY & EQUIPMENT	$	1,567,121		$	1,686,287
OTHER ASSETS
Investment in wholly-owned subsidiary (Savient Pharma Holdings, SPHI)	$	147,259,564		$	147,259,564
Investment in wholly-owned subsidiary (Savient Pharma Ireland, Limited, SPIL)		134			134
TOTAL OTHER ASSETS	$	147,259,698		$	147,259,698
TOTAL ASSETS	$	173,986,806		$	175,057,326

SAVIENT_MOR_3 FORM MOR-3 (04/07)

LIABILITIES AND OWNER EQUITY	BOOK VALUE AT JANUARY 31, 2014		BOOK VALUE ON PETITION DATE
LIABILITIES NOT SUBJECT TO COMPROMISE (Postpetition)
Accounts payable	$	30	$	12,972
Accrued expenses
Accrued professional fees	$	7,299,913	$	-
Accrued employee expense reimbursement		-		13,093
Other accrued postpetition liabilities (see attached schedule)		102,005		-
Total accrued expenses	$	7,401,918	$	13,093
Other liabilities not subject to compromise
Accrued royalties payable	$	-	$	943,189
Deferred revenue		-		936,535
Reserve for returns		369,631		407,355
Reserve for chargeback’s		32,099		264,528
Reserve for Medicaid claims		305,448		241,584
Capital lease liability		-		185,672
Accrued distribution fees		59,498		44,528
Accrued Delaware franchise taxes		38,920		58,380
Accrued sales and use taxes		3,424		-
Accrued payroll taxes (Puerto Rico)		-		-
Total other liabilities not subject to compromise	$	809,020	$	3,081,771
TOTAL LIABILITIES NOT SUBJECT TO COMPRMISE (POSTPETITION LIABILITIES)	$	8,210,968	$	3,107,836
LIABILITIES SUBJECT TO COMPROMISE (Pre-Petition)
Accounts payable	$	849,096	$	1,402,335
Accrued expenses
Other accrued pre-petition liabilities (see attached schedule)	$	1,239,586	$	1,818,953
Total accrued expenses	$	1,239,586	$	1,818,953
Other liabilities subject to compromise
Senior Secured 2019 Notes	$	144,257,695	$	144,257,695
Subordinated Debt 2018 Convertible Notes		99,555,240		99,555,240
Intercompany loan payable to wholly owned subsidiary Savient Pharma Holdings, SPHI		29,204,944		15,504,588
Accrued Purchase commitment reserve		-		3,771,066
Accrued Severance liability		2,102,695		2,102,695
Warrant Liability		1,479,776		1,479,776
Accrued home office bonuses		1,370,749		1,370,749
Accrued Sales commissions		733,400		820,357
Embedded conversion features liability 2018 convertible notes		848,100		848,100
Accrued retention bonuses		821,030		821,030
Accrued vacation		-		281,395
Employee benefit related (flex spending liabilities)		-		50,597
Total other liabilities subject to compromise	$	280,373,629	$	270,863,288
TOTAL LIABILITIES SUBJECT TO COMPRIMISE (PRE-PETITION)	$	282,462,311	$	274,084,576
TOTAL LIABILITIES	$	290,673,279	$	277,192,412
OWNER EQUITY
Common Stock	$	736,949	$	736,949
Additional Paid-In Capital		401,417,969		400,739,096
Retained Earnings - Pre-Petition		(504,255,122)		(503,611,131)
Retained Earnings - Postpetition		(14,586,269)
NET OWNER EQUITY	$	(116,686,473)	$	(102,135,086)
TOTAL LIABILITIES AND OWNERS’ EQUITY	$	173,986,806	$	175,057,326

*“Insider” is defined in 11 U.S.C. Section 101(31). -      

SAVIENT_MOR_3 FORM MOR-3 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SPHI (13-12681): BALANCE SHEET

ASSETS	BOOK VALUE AT JANUARY 31, 2014		BOOK VALUE ON PETITION DATE
CURRENT ASSETS
Cash and cash equivalents
PNC Bank business operating account		3,241,587		3,241,604
Fidelity U.S. Treasury money market account		-		13,700,283
Total cash and cash equivalents	$	3,241,587	$	16,941,887
TOTAL CURRENT ASSETS	$	3,241,587	$	16,941,887
TOTAL ASSETS	$	3,241,587	$	16,941,887
OWNER EQUITY
Common Stock	$	1	$	1
Additional Paid-In Capital		147,259,563		147,259,563
Retained Earnings - Pre-Petition		(130,317,677)		(130,317,677)
Retained Earnings - Postpetition		(13,700,300)		-
NET OWNER EQUITY	$	3,241,587	$	16,941,887
TOTAL LIABILITIES AND OWNERS’ EQUITY	$	3,241,587	$	16,941,887

SPHI_MOR_3 FORM MOR-3 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of January 31, 2014 and paid in the ordinary course by the Debtor

SUMMARY OF UNPAID POSTPETITION DEBTS

As reflected below, Debtor is current on all postpetition debts.

	Number of Days Past Due
	Current		0-30		31-60		61-90		Over 90		Total
Accounts Payable	$	30	$	-	$	-	$	-	$	-	$	30
Employee Expenses Payable (Concur)		-		-		-		-		-	$	-
Wages Payable		-		-		-		-		-		-
Taxes Payable		-		-		-		-		-		-
Rent/Leases-Building		-		-		-		-		-		-
Rent/Leases-Equipment		-		-		-		-		-		-
Secured Debt/Adequate Protection Payments		-		-		-		-		-		-
Professional Fees		-		-		-		-		-		-
Amounts Due to Insiders		-		-		-		-		-		-
Total Postpetition Debts	$	30	$	-	$	-	$	-	$	-	$	30

SAVIENT_MOR_4 FORM MOR-4 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SPHI (13-12681): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of January 31, 2014 and paid in the ordinary course by the Debtor.

SUMMARY OF UNPAID POSTPETITION DEBTS

The Debtor is current on all postpetition debts.

SPHI_MOR_4 FORM MOR-4 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SAVIENT (13-12680): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

Accounts Receivable Reconciliation		BOOK VALUE AT   JANUARY 31, 2014			BOOK VALUE AT  DECEMBER 31, 2013			BOOK VALUE AT  NOVEMBER 30, 2013			BOOK VALUE AT  OCTOBER 31, 2013
Total Accounts Receivable at the beginning of the reporting period		$	7,434,952		$	7,372,339		$	7,116,283			7,045,577
+ Amounts billed during the period			1,162,843			3,365,207			2,570,042			2,177,755
- Amounts collected during the period			(2,168,659	)		(2,294,795	)		(1,243,215	)		(1,455,908	)
- Discounts and Chargeback’s			(457,211	)		(953,422	)		(1,036,869	)		(600,708	)
- Return Credits			(5,037	)		(19,364	)		(2,551	)		(20,378	)
- Prompt Pay Discounts			(29,916	)		(35,013	)		(31,351	)		(30,055	)
Total Accounts Receivable at the end of the reporting period		$	5,936,972		$	7,434,952		$	7,372,339		$	7,116,283
- Provision for discounts			-			(49,626	)		(34,907	)		(59,679	)
+ Accounts receivable other			73,838			67,200			47,612			22,795
Total Accounts Receivable, Net at the end of the reporting period		$	6,010,810		$	7,452,526		$	7,385,044		$	7,079,399
Accounts Receivable Aging		BOOK VALUE AT JANUARY 31, 2014			BOOK VALUE AT DECEMBER 31, 2013			BOOK VALUE AT NOVEMBER 30, 2013			BOOK VALUE AT OCTOBER 31, 2013
0 - 30 days old		$	2,815,441		$	4,635,949		$	5,679,858			5,672,068
31 - 60 days old			315,136			1,177,031			263,279			-
61 - 90 days old			1,125,299			187,404			6,427			21,440
91+ days old			1,681,094			1,434,568			1,422,775			1,422,775
Total Accounts Receivable at the end of the reporting period		$	5,936,971		$	7,434,952		$	7,372,339		$	7,116,283
- Provision for discounts			-			(49,626	)		(34,907	)		(59,679	)
+ Accounts receivable other			73,838			67,200			47,612			22,795
Total Accounts Receivable, Net at the end of the reporting period		$	6,010,809		$	7,452,526		$	7,385,044		$	7,079,399
DEBTOR QUESTIONNAIRE
Must be completed each month		Yes			No
1.	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X*
2.	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.					X
3.	Have all postpetition tax returns been timely filed? If no, provide an explanation below.		X
4.	Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.		X
5.	Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.		X**

*Assets were sold outside the ordinary course of business pursuant to Court orders [Docket Nos. 251, 332].

**PNC AR Lockbox was opened on January 10, 2014, to segregate receipts on current accounts receivable balances from normal operating cash.

SAVIENT_MOR_5 FORM MOR-5 (04/07)

In re: Savient Pharmaceuticals, Inc., et al	Case No. 13-12680 (MFW)
Debtor	Reporting Period: January 1, 2014 - January 31, 2014

SPHI(13-12681): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

Accounts Receivable Reconciliation		Amount
NOT APPLICABLE		$	-
Accounts Receivable Aging		Amount
NOT APPLICABLE		$	-
DEBTOR QUESTIONNAIRE
Must be completed each month		Yes		No
1.	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.			X
2.	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.			X
3.	Have all postpetition tax returns been timely filed? If no, provide an explanation below.		X
4.	Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.		X
5.	Has any bank account been opened during the reporting period? If yes, provide			X
	documentation identifying the opened account(s). If an investment account has
	been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.

SPHI_MOR_5 FORM MOR-5 (04/07)